Table 4 Risk factor analysis for venous thromboembolism (VTE) occurrence within 1 year after lung cancer diagnosis
| Â | Â | Univariate | Multivariate** | ||
|---|---|---|---|---|---|
| Â | Â | sHR (95% CI) | p-value | sHR (95% CI) | p-value |
Age | <  55 | – | – | – | – |
55–65 | 0.89 (0.61–1.28) | 0.519 | 0.94 (0.64–1.38) | 0.758 | |
65–75 | 0.66 (0.45–0.99) | 0.042 | 0.78 (0.52–1.17) | 0.232 | |
≥ 75 | 0.42 (0.27–0.65) | 0.0001 | 0.65 (0.41–1.04) | 0.071 | |
Gender | Male | – | – | – | – |
Female | 1.07 (0.80–1.43) | 0.650 | 1.10 (0.82–1.48) | 0.523 | |
Metastasis | 2.86 (2.12–3.86) | < 0.0001 | 1.83 (1.30–2.58) | 0.0005 | |
VTE concomitant with cancer diagnosis* | 4.26 (1.67–10.88) | 0.003 | 4.07 (1.57–10.52) | 0.004 | |
Lung cancer surgery | 0.96 (0.64–1.44) | 0.955 |  |  | |
Other surgery | 2.05 (1.48–2.82) | < 0.0001 | 1.49 (1.06–2.09) | 0.022 | |
Chemotherapy | 4.63 (3.45–6.23) | < 0.0001 | 3.44 (2.44–4.85) | < 0.0001 | |
Bevacizumab | 2.39 (1.29–4.42) | 0.006 |  |  | |
Oral targeted therapy | 1.19 (0.56–2.54) | 0.655 |  |  | |
Radiotherapy | 1.95 (1.41–2.71) | < 0.0001 |  |  | |
Blood transfusion | 1.91 (1.16–3.15) | 0.012 |  |  | |
Non-surgical hospitalization | 1.53 (1.16–2.03) | 0.003 |  |  | |